​

Pacific Biosciences of California (PACB) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

PACB Stock Forecast

Pacific Biosciences of California (PACB) stock forecast, based on 15 Wall Street analysts, predicts a 12-month average price target of $3.00, with a high of $4.00 and a low of $2.00. This represents a 156.41% increase from the last price of $1.17.

$1 $2 $3 $4 $5 $6 $7 $8 $9 $10 High: $4 Avg: $3 Low: $2 Last Closed Price: $1.17

PACB Stock Rating

Pacific Biosciences of California stock's rating consensus is Buy, based on 15 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 8 Buy (53.33%), 7 Hold (46.67%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 15 0 7 8 Strong Sell Sell Hold Buy Strong Buy

PACB Price Target Upside V Benchmarks

TypeNameUpside
StockPacific Biosciences of California156.41%
SectorHealthcare Stocks 35.25%
IndustryMedical Device Stocks21.20%

Price Target Trends

1M3M12M
# Anlaysts--5
Avg Price Target--$2.90
Last Closing Price$1.17$1.17$1.17
Upside/Downside--147.86%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 25168--15
Mar, 25168--15
Feb, 25168--15
Jan, 25168--15
Dec, 24168--15
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jun 03, 2024Tycho PetersonJefferies$4.00$1.79123.46%241.88%
May 13, 2024Tejas SavantMorgan Stanley$4.00$1.98102.02%241.88%
May 13, 2024David WestenbergPiper Sandler$2.00$1.7712.99%70.94%
May 10, 2024Luke SergottBarclays$2.00$1.7216.28%70.94%
Apr 18, 2024Matthew SykesGoldman Sachs$2.50$1.4078.57%113.68%
Apr 16, 2024Kyle MiksonCanaccord Genuity$3.50$1.40150.00%199.15%
Nov 16, 2022Canaccord Genuity$14.00$10.8129.51%1096.58%
Aug 17, 2022David WestenbergPiper Sandler$7.50$7.61-1.45%541.03%
May 15, 2022David WestenbergPiper Sandler$6.00$5.842.74%412.82%
Jan 12, 2022David WestenbergPiper Sandler$20.00$14.4538.41%1609.40%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Mar 25, 2025ScotiabankOutperformOutperformhold
Aug 28, 2024Morgan StanleyUnderperformUnderperformhold
Aug 12, 2024Morgan StanleyBuyBuyhold
Jun 03, 2024JefferiesBuyinitialise
May 13, 2024Morgan StanleyEqual-WeightEqual-Weighthold
May 13, 2024Piper SandlerNeutralNeutralhold
May 10, 2024BarclaysEqual-WeightEqual-Weighthold
Apr 18, 2024ScotiabankSector OutperformSector Outperformhold
Apr 18, 2024BernsteinOutperformOutperformhold
Apr 18, 2024Goldman SachsNeutraldowngrade

Financial Forecast

EPS Forecast

Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$0.18$-0.89$-1.32$-1.21$-1.12----
Avg Forecast$0.17$-0.85$-1.39$-1.18$-1.35$-0.68$-0.56$-0.45$-0.36
High Forecast$0.19$-0.78$-1.29$-1.15$-1.17$-0.58$-0.41$-0.33$-0.33
Low Forecast$0.16$-0.92$-1.50$-1.19$-1.95$-0.87$-0.67$-0.65$-0.39
Surprise %5.88%4.71%-5.04%2.54%-17.04%----

Revenue Forecast

$50M $130M $210M $290M $370M $450M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$78.89M$130.51M$128.30M$200.52M$154.01M----
Avg Forecast$76.42M$130.49M$127.45M$199.19M$155.28M$187.16M$249.01M$330.07M$414.15M
High Forecast$81.29M$138.80M$135.44M$200.94M$155.43M$197.48M$249.98M$338.87M$440.68M
Low Forecast$71.25M$121.66M$120.53M$196.74M$155.03M$179.12M$248.05M$321.26M$390.44M
Surprise %3.23%0.02%0.67%0.67%-0.82%----

Net Income Forecast

$-500M $-390M $-280M $-170M $-60M $50M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$29.40M$-181.22M$-296.93M$-306.74M$-308.65M----
Avg Forecast$16.75M$-177.70M$-191.47M$-306.74M$-394.24M$-203.45M$-170.81M$-135.20M$-91.31M
High Forecast$39.63M$-136.17M$-146.59M$-235.35M$-297.80M$-147.72M$-104.55M$-83.70M$-84.51M
Low Forecast$-6.13M$-219.22M$-236.35M$-378.12M$-493.82M$-220.28M$-171.09M$-164.86M$-98.91M
Surprise %75.53%1.98%55.08%--21.71%----

PACB Forecast FAQ

Is Pacific Biosciences of California stock a buy?

Pacific Biosciences of California stock has a consensus rating of Buy, based on 15 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 8 Buy, 7 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Pacific Biosciences of California is a favorable investment for most analysts.

What is Pacific Biosciences of California's price target?

Pacific Biosciences of California's price target, set by 15 Wall Street analysts, averages $3 over the next 12 months. The price target range spans from $2 at the low end to $4 at the high end, suggesting a potential 156.41% change from the previous closing price of $1.17.

How does Pacific Biosciences of California stock forecast compare to its benchmarks?

Pacific Biosciences of California's stock forecast shows a 156.41% upside, outperforming the average forecast for the healthcare stocks sector (35.25%) and outperforming the medical device stocks industry (21.20%).

What is the breakdown of analyst ratings for Pacific Biosciences of California over the past three months?

  • April 2025: 6.67% Strong Buy, 40.00% Buy, 53.33% Hold, 0% Sell, 0% Strong Sell.
  • March 2025: 6.67% Strong Buy, 40.00% Buy, 53.33% Hold, 0% Sell, 0% Strong Sell.
  • February 2025: 6.67% Strong Buy, 40.00% Buy, 53.33% Hold, 0% Sell, 0% Strong Sell.

What is Pacific Biosciences of California’s EPS forecast?

Pacific Biosciences of California's average annual EPS forecast for its fiscal year ending in December 2025 is $-0.68, marking a -39.29% decrease from the reported $-1.12 in 2024. Estimates for the following years are $-0.56 in 2026, $-0.45 in 2027, and $-0.36 in 2028.

What is Pacific Biosciences of California’s revenue forecast?

Pacific Biosciences of California's average annual revenue forecast for its fiscal year ending in December 2025 is $187.16M, reflecting a 21.52% increase from the reported $154.01M in 2024. The forecast for 2026 is $249.01M, followed by $330.07M for 2027, and $414.15M for 2028.

What is Pacific Biosciences of California’s net income forecast?

Pacific Biosciences of California's net income forecast for the fiscal year ending in December 2025 stands at $-203M, representing a -34.08% decrease from the reported $-309M in 2024. Projections indicate $-171M in 2026, $-135M in 2027, and $-91.306M in 2028.